CL2013000788A1 - Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer. - Google Patents
Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer.Info
- Publication number
- CL2013000788A1 CL2013000788A1 CL2013000788A CL2013000788A CL2013000788A1 CL 2013000788 A1 CL2013000788 A1 CL 2013000788A1 CL 2013000788 A CL2013000788 A CL 2013000788A CL 2013000788 A CL2013000788 A CL 2013000788A CL 2013000788 A1 CL2013000788 A1 CL 2013000788A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- leukotriene
- fibrotic
- oxadiazole
- allergic
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000000172 allergic effect Effects 0.000 title abstract 2
- 208000010668 atopic eczema Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 230000003176 fibrotic effect Effects 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000002617 leukotrienes Chemical class 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 title 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 title 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 abstract 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 abstract 1
- 108091006088 activator proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38573310P | 2010-09-23 | 2010-09-23 | |
| US201161533349P | 2011-09-12 | 2011-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000788A1 true CL2013000788A1 (es) | 2013-06-28 |
Family
ID=44720163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000788A CL2013000788A1 (es) | 2010-09-23 | 2013-03-21 | Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8575201B2 (en:Method) |
| EP (1) | EP2619197B1 (en:Method) |
| JP (1) | JP5713511B2 (en:Method) |
| KR (1) | KR20130109122A (en:Method) |
| CN (1) | CN103261193A (en:Method) |
| AU (1) | AU2011305667A1 (en:Method) |
| BR (1) | BR112013008638A2 (en:Method) |
| CA (1) | CA2812449A1 (en:Method) |
| CL (1) | CL2013000788A1 (en:Method) |
| CO (1) | CO6710902A2 (en:Method) |
| EA (1) | EA201300389A1 (en:Method) |
| EC (1) | ECSP13012548A (en:Method) |
| IN (1) | IN2013DN02555A (en:Method) |
| MX (1) | MX2013003202A (en:Method) |
| PE (1) | PE20131398A1 (en:Method) |
| PH (1) | PH12013500545A1 (en:Method) |
| SG (1) | SG188604A1 (en:Method) |
| WO (1) | WO2012040139A1 (en:Method) |
| ZA (1) | ZA201301747B (en:Method) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3150164B2 (ja) | 1991-05-01 | 2001-03-26 | 電気化学工業株式会社 | セメント混和材及びセメント組成物 |
| WO2012027322A1 (en) * | 2010-08-26 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| PE20131398A1 (es) | 2010-09-23 | 2013-12-19 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos |
| EP2619196B1 (en) * | 2010-09-23 | 2015-09-16 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| WO2014121055A2 (en) * | 2013-02-04 | 2014-08-07 | Janssen Pharmaceutica Nv | Flap modulators |
| ES2596248T3 (es) | 2013-11-26 | 2017-01-05 | Citrage | N-Carbamoilputrescina para mejorar la síntesis de proteínas musculares |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2380759A1 (en) | 1999-08-06 | 2001-02-15 | Janssen Pharmaceutica N.V. | Interleukin-5 inhibiting 6-azauracil derivatives |
| JP2007502300A (ja) * | 2003-08-13 | 2007-02-08 | カイロン コーポレイション | Ｇｓｋ−３インヒビターおよびその使用 |
| US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
| EP1814877B1 (en) | 2004-10-18 | 2009-03-11 | Merck & Co., Inc. | Diphenyl substituted alkanes as flap inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CA2648555A1 (en) * | 2006-04-11 | 2007-10-25 | Merck & Co., Inc. | Diaryl substituted alkanes |
| AU2007265475B2 (en) | 2006-06-26 | 2010-08-19 | Amgen Inc. | Methods for treating atherosclerosis |
| WO2008030369A1 (en) * | 2006-09-01 | 2008-03-13 | Merck & Co., Inc. | Inhibitors of 5 -lipoxygenase activating protein ( flap) |
| CA2683948A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2008156721A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Diphenyl substituted alkanes |
| CA2702225A1 (en) | 2007-10-10 | 2009-04-16 | Merck Sharp & Dohme Corp. | Diphenyl substituted cycloalkanes |
| DE102008037790A1 (de) * | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| CA2741666C (en) * | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| WO2010089686A1 (en) | 2009-02-04 | 2010-08-12 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
| CA2798514A1 (en) | 2010-05-12 | 2011-11-17 | P. Jeffrey Conn | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| KR20130100105A (ko) * | 2010-08-16 | 2013-09-09 | 베링거 인겔하임 인터내셔날 게엠베하 | 류코트리엔 생성 억제제인 옥사디아졸 |
| WO2012027322A1 (en) * | 2010-08-26 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| EP2619196B1 (en) * | 2010-09-23 | 2015-09-16 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| PE20131398A1 (es) | 2010-09-23 | 2013-12-19 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos |
-
2011
- 2011-09-20 PE PE2013000629A patent/PE20131398A1/es not_active Application Discontinuation
- 2011-09-20 KR KR1020137007287A patent/KR20130109122A/ko not_active Withdrawn
- 2011-09-20 WO PCT/US2011/052254 patent/WO2012040139A1/en not_active Ceased
- 2011-09-20 US US13/237,112 patent/US8575201B2/en active Active
- 2011-09-20 PH PH1/2013/500545A patent/PH12013500545A1/en unknown
- 2011-09-20 SG SG2013020300A patent/SG188604A1/en unknown
- 2011-09-20 EA EA201300389A patent/EA201300389A1/ru unknown
- 2011-09-20 IN IN2555DEN2013 patent/IN2013DN02555A/en unknown
- 2011-09-20 CN CN2011800565586A patent/CN103261193A/zh active Pending
- 2011-09-20 MX MX2013003202A patent/MX2013003202A/es active IP Right Grant
- 2011-09-20 CA CA2812449A patent/CA2812449A1/en not_active Abandoned
- 2011-09-20 JP JP2013530221A patent/JP5713511B2/ja active Active
- 2011-09-20 BR BR112013008638A patent/BR112013008638A2/pt not_active IP Right Cessation
- 2011-09-20 EP EP11761775.3A patent/EP2619197B1/en active Active
- 2011-09-20 AU AU2011305667A patent/AU2011305667A1/en not_active Abandoned
-
2013
- 2013-03-07 ZA ZA2013/01747A patent/ZA201301747B/en unknown
- 2013-03-21 CL CL2013000788A patent/CL2013000788A1/es unknown
- 2013-03-22 CO CO13057875A patent/CO6710902A2/es not_active Application Discontinuation
- 2013-04-11 EC ECSP13012548 patent/ECSP13012548A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6710902A2 (es) | 2013-07-15 |
| PH12013500545A1 (en) | 2013-05-06 |
| BR112013008638A2 (pt) | 2016-06-21 |
| MX2013003202A (es) | 2013-04-24 |
| EP2619197A1 (en) | 2013-07-31 |
| CN103261193A (zh) | 2013-08-21 |
| EA201300389A1 (ru) | 2013-09-30 |
| WO2012040139A1 (en) | 2012-03-29 |
| US8575201B2 (en) | 2013-11-05 |
| KR20130109122A (ko) | 2013-10-07 |
| JP5713511B2 (ja) | 2015-05-07 |
| ZA201301747B (en) | 2014-08-27 |
| SG188604A1 (en) | 2013-04-30 |
| CA2812449A1 (en) | 2012-03-29 |
| PE20131398A1 (es) | 2013-12-19 |
| AU2011305667A1 (en) | 2013-03-21 |
| IN2013DN02555A (en:Method) | 2015-08-07 |
| ECSP13012548A (es) | 2013-06-28 |
| JP2013537909A (ja) | 2013-10-07 |
| EP2619197B1 (en) | 2015-08-05 |
| US20120295896A1 (en) | 2012-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2013000788A1 (es) | Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer. | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| JP2011256183A5 (en:Method) | ||
| EA201000775A1 (ru) | Ингибиторы бета-лактамазы | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| EA201400838A1 (ru) | ЗАМЕЩЕННЫЕ АМИДИНОМ β-ЛАКТАМЫ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ | |
| BR112015011112A2 (pt) | composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença. | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| AR089993A1 (es) | Macrociclos peptidomimeticos | |
| AR090339A1 (es) | Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica | |
| JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
| MX2021001169A (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. | |
| PL3023788T3 (pl) | Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów | |
| CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| EA201400178A1 (ru) | Лечение рака молочной железы |